Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 224

1.

The success story of trastuzumab emtansine, a targeted therapy in HER2-positive breast cancer.

Diéras V, Bachelot T.

Target Oncol. 2014 Jun;9(2):111-22. doi: 10.1007/s11523-013-0287-4. Epub 2013 Jul 14. Review.

PMID:
23852665
2.

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer.

Boyraz B, Sendur MA, Aksoy S, Babacan T, Roach EC, Kizilarslanoglu MC, Petekkaya I, Altundag K.

Curr Med Res Opin. 2013 Apr;29(4):405-14. doi: 10.1185/03007995.2013.775113. Epub 2013 Mar 1. Review.

PMID:
23402224
3.

Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.

Corrigan PA, Cicci TA, Auten JJ, Lowe DK.

Ann Pharmacother. 2014 Nov;48(11):1484-93. doi: 10.1177/1060028014545354. Epub 2014 Jul 31. Review.

PMID:
25082874
4.

A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.

Krop IE, LoRusso P, Miller KD, Modi S, Yardley D, Rodriguez G, Guardino E, Lu M, Zheng M, Girish S, Amler L, Winer EP, Rugo HS.

J Clin Oncol. 2012 Sep 10;30(26):3234-41. doi: 10.1200/JCO.2011.40.5902. Epub 2012 May 29.

5.

[Trastuzumab emtansine (Kadcyla(®)) approval in HER2-positive metastatic breast cancers].

Guerin M, Sabatier R, Gonçalves A.

Bull Cancer. 2015 Apr;102(4):390-7. doi: 10.1016/j.bulcan.2015.02.007. Epub 2015 Mar 16. French.

PMID:
25790739
6.
7.

Trastuzumab emtansine: a novel antibody-drug conjugate for HER2-positive breast cancer.

Krop I, Winer EP.

Clin Cancer Res. 2014 Jan 1;20(1):15-20. doi: 10.1158/1078-0432.CCR-13-0541. Epub 2013 Oct 17.

8.

Trastuzumab emtansine for the treatment of HER2-positive metastatic breast cancer.

Haddley K.

Drugs Today (Barc). 2013 Nov;49(11):701-15. doi: 10.1358/dot.2013.49.11.2020937. Review.

PMID:
24308017
9.

[Antibody-drug conjugates in oncology: from the concept to trastuzumab emtansine (T-DM1)].

Gonçalves A, Trédan O, Villanueva C, Dumontet C.

Bull Cancer. 2012 Dec;99(12):1183-91. doi: 10.1684/bdc.2012.1669. Review. French.

PMID:
23247898
10.

Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.

Krop IE, Kim SB, González-Martín A, LoRusso PM, Ferrero JM, Smitt M, Yu R, Leung AC, Wildiers H; TH3RESA study collaborators.

Lancet Oncol. 2014 Jun;15(7):689-99. doi: 10.1016/S1470-2045(14)70178-0. Epub 2014 May 2.

PMID:
24793816
11.

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, Pegram M, Oh DY, Diéras V, Guardino E, Fang L, Lu MW, Olsen S, Blackwell K; EMILIA Study Group.

N Engl J Med. 2012 Nov 8;367(19):1783-91. doi: 10.1056/NEJMoa1209124. Epub 2012 Oct 1. Erratum in: N Engl J Med. 2013 Jun 20;368(25):2442.

12.

Phase II randomized study of trastuzumab emtansine versus trastuzumab plus docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Hurvitz SA, Dirix L, Kocsis J, Bianchi GV, Lu J, Vinholes J, Guardino E, Song C, Tong B, Ng V, Chu YW, Perez EA.

J Clin Oncol. 2013 Mar 20;31(9):1157-63. doi: 10.1200/JCO.2012.44.9694. Epub 2013 Feb 4. Erratum in: J Clin Oncol. 2013 Aug 10;31(23):2977.

13.

Phase I and pharmacokinetic study of trastuzumab emtansine in Japanese patients with HER2-positive metastatic breast cancer.

Yamamoto H, Ando M, Aogi K, Iwata H, Tamura K, Yonemori K, Shimizu C, Hara F, Takabatake D, Hattori M, Asakawa T, Fujiwara Y.

Jpn J Clin Oncol. 2015 Jan;45(1):12-8. doi: 10.1093/jjco/hyu160. Epub 2014 Oct 20.

14.

Ado-trastuzumab emtansine (T-DM1): a novel antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer.

Baron JM, Boster BL, Barnett CM.

J Oncol Pharm Pract. 2015 Apr;21(2):132-42. doi: 10.1177/1078155214527144. Epub 2014 Mar 27. Review.

PMID:
24682654
15.

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer.

LoRusso PM, Weiss D, Guardino E, Girish S, Sliwkowski MX.

Clin Cancer Res. 2011 Oct 15;17(20):6437-47. doi: 10.1158/1078-0432.CCR-11-0762. Review.

16.

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review.

Mathew J, Perez EA.

Curr Opin Oncol. 2011 Nov;23(6):594-600. doi: 10.1097/CCO.0b013e32834b895c. Review.

PMID:
21986845
17.

Trastuzumab emtansine in advanced human epidermal growth factor receptor 2-positive breast cancer.

Van den Mooter T, Teuwen LA, Rutten A, Dirix L.

Expert Opin Biol Ther. 2015 May;15(5):749-60. doi: 10.1517/14712598.2015.1036026. Review.

PMID:
25865453
18.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

Burris HA 3rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, Amler L, Zheng M, Chu YW, Klencke B, O'Shaughnessy JA.

J Clin Oncol. 2011 Feb 1;29(4):398-405. doi: 10.1200/JCO.2010.29.5865. Epub 2010 Dec 20.

19.

Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer.

Patel KC, Hageman K, Cooper MR.

Am J Health Syst Pharm. 2014 Apr 1;71(7):537-48. doi: 10.2146/ajhp130342. Review.

PMID:
24644113
20.

Trastuzumab emtansine in human epidermal growth factor receptor 2-positive metastatic breast cancer: an integrated safety analysis.

Diéras V, Harbeck N, Budd GT, Greenson JK, Guardino AE, Samant M, Chernyukhin N, Smitt MC, Krop IE.

J Clin Oncol. 2014 Sep 1;32(25):2750-7. doi: 10.1200/JCO.2013.54.4999. Epub 2014 Jul 14.

Items per page

Supplemental Content

Write to the Help Desk